{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:46:06Z","timestamp":1790423166449,"version":"4.1.0"},"reference-count":33,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25028","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:07:52Z","timestamp":1753826872000},"page":"174-179","source":"Crossref","is-referenced-by-count":7,"title":["BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL"],"prefix":"10.3960","volume":"65","author":[{"given":"Kensuke","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, Kochi Medical School Hospital, Nankoku, Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Kunisawa","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, Kochi Medical School Hospital, Nankoku, Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Nawaratne V, Sondhi AK, Abdel-Wahab O, Taylor J. New Means and Challenges in the Targeting of BTK. Clin Cancer Res. 2024; 30: 2333-2341.","DOI":"10.1158\/1078-0432.CCR-23-0409"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Jain N, Wierda WG, O\u2019Brien S. Chronic lymphocytic leukaemia. Lancet. 2024; 404: 694-706.","DOI":"10.1016\/S0140-6736(24)00595-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2025; 145: 673-682.","DOI":"10.1182\/blood.2023022353"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Barr PM, Owen C, Robak T <i>et al.<\/i> Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022; 6: 3440-3450.","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020; 2020: 336-345.","DOI":"10.1182\/hematology.2020000118"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Quek LS, Bolen J, Watson SP. A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998; 8: 1137-1140.","DOI":"10.1016\/S0960-9822(98)70471-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Barf T, Covey T, Izumi R <i>et al.<\/i> Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther. 2017; 363: 240-252.","DOI":"10.1124\/jpet.117.242909"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003; 102: 3592-3599.","DOI":"10.1182\/blood-2003-04-1142"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bye AP, Unsworth AJ, Desborough MJ <i>et al.<\/i> Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017; 1: 2610-2623.","DOI":"10.1182\/bloodadvances.2017011999"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Quint\u00e1s-Cardama A, Kantarjian H, Ravandi F <i>et al.<\/i> Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009; 115: 2482-2490.","DOI":"10.1002\/cncr.24257"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gratacap MP, Martin V, Val\u00e9ra MC <i>et al.<\/i> The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009; 114: 1884-1892.","DOI":"10.1182\/blood-2009-02-205328"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ratain MJ, Tannock IF, Lichter AS. The dosing of ibrutinib and related Bruton\u2019s tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022; 6: 5041-5044.","DOI":"10.1182\/bloodadvances.2022007793"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Portell CA, Wages NA, Kahl BS <i>et al.<\/i> Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2022; 6: 1490-1498.","DOI":"10.1182\/bloodadvances.2021005357"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Seymour JF, Byrd JC, Ghia P <i>et al.<\/i> Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023; 142: 687-699.","DOI":"10.1182\/blood.2022018818"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Wang ML, Jurczak W, Zinzani PL <i>et al.<\/i> Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023; 41: 3988-3997.","DOI":"10.1200\/JCO.23.00562"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Lamanna N, Tam CS, Woyach JA <i>et al.<\/i> Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. EJHaem. 2024; 5: 929-939.","DOI":"10.1002\/jha2.1013"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Sakai K, Someya T, Harada K <i>et al.<\/i> Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab. Haematologica. 2020; 105: 2631-2638.","DOI":"10.3324\/haematol.2019.235549"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kaneko M, Cuyun-Lira O, Takafuta T <i>et al.<\/i> Mechanisms of platelet retention in the collagen-coated-bead column. J Lab Clin Med. 2003; 142: 258-267.","DOI":"10.1016\/S0022-2143(03)00133-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yamazaki M, Ohnishi T, Hosokawa K <i>et al.<\/i> Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost. 2016; 14: 1788-1797.","DOI":"10.1111\/jth.13391"},{"key":"20","unstructured":"20 Sakayori T, Egashira M, Nakajima K <i>et al.<\/i> Analytical Evalua-tion of Platelet Aggregation Level on a Fully Automated Coagulation Analyzer CN-6000, and a Case Study of an Initial Absorbance of Platelet-rich Plasma. Sysmex Journal Inter-national. 2024; 34: 1."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Li P, Xu B, Xu J <i>et al.<\/i> Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma. Int J Mol Sci. 2023; 24: 14097.","DOI":"10.3390\/ijms241814097"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Byrd JC, Harrington B, O\u2019Brien S <i>et al.<\/i> Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016; 374: 323-332.","DOI":"10.1056\/NEJMoa1509981"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Bye AP, Kriek N, Sage T <i>et al.<\/i> Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica. 2023; 108: 1429-1435.","DOI":"10.3324\/haematol.2022.281402"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Patel V, Balakrishnan K, Bibikova E <i>et al.<\/i> Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017; 23: 3734-3743.","DOI":"10.1158\/1078-0432.CCR-16-1446"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Bye AP, Unsworth AJ, Vaiyapuri S <i>et al.<\/i> Ibrutinib Inhibits Platelet Integrin \u03b1IIb\u03b23 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. Arterioscler Thromb Vasc Biol. 2015; 35: 2326-2335.","DOI":"10.1161\/ATVBAHA.115.306130"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Dobie G, Kuriri FA, Omar MMA <i>et al.<\/i> Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Adv. 2019; 3: 4298-4311.","DOI":"10.1182\/bloodadvances.2019000640"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Kozarac S, Vukovic V, Fradley M, Antic D. BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies. Blood Rev. 2025; 70: 101268.","DOI":"10.1016\/j.blre.2025.101268"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Mori J, Nagy Z, Di Nunzio G <i>et al.<\/i> Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148. Blood. 2018; 131: 1122-1144.","DOI":"10.1182\/blood-2017-02-768077"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Mendez-Ruiz A, Lossos IS, Cohen MG. Bleeding Risk With Antiplatelets and Bruton\u2019s Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention. J Soc Cardiovasc Angiogr Interv. 2023; 2: 100608.","DOI":"10.1016\/j.jscai.2023.100608"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Infeld M, Friede KA, San TR <i>et al.<\/i> Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. J Thromb Thrombolysis. 2021; 51: 249-259.","DOI":"10.1007\/s11239-020-02327-w"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Ikeda T, Taniguchi R, Watanabe S <i>et al.<\/i> Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan. Circ J. 2010; 74: 1227-1235.","DOI":"10.1253\/circj.CJ-09-0927"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Montalto C, Costa F, Leonardi S <i>et al.<\/i> Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9: 220-230.","DOI":"10.1093\/ehjcvp\/pvac065"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/3\/65_25028\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:43:56Z","timestamp":1759553036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/3\/65_25028\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25028","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25028"}}